RS-2025-02213331

Development of Selective TYK2 Allosteric Domain Inhibitors as Candidate Therapeutics for Autoimmune Diseases

AZothBio, Inc.

IMMUNOLOGY | Candidate

Product Type	Small molecules
Indication	Autoimmune disease (Psoriasis)
Target	TYK2
MoA(Mechanism of Action)	Selectively binds to the TYK2 pseudokinase (JH2) domain as an allosteric inhibitor to modulate TYK2 activity
Competitiveness	• Deucravacitinib, approved in 2022 for the same target, is in use; our candidate shows much higher selectivity. • Well-defined MoA enables strong potential for indication expansion.
Development Stage	Candidate
Route of Administration	P.O